The closing price of Heron Therapeutics Inc (NASDAQ: HRTX) was $2.93 for the day, down -0.68% from the previous closing price of $2.95. On the day, 1648590 shares were traded.
Ratios:
Our analysis of HRTX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.84 and its Current Ratio is at 2.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on March 13, 2024, Reiterated its Buy rating but revised its target price to $5 from $4 previously.
On May 27, 2020, Guggenheim started tracking the stock assigning a Buy rating and target price of $24.
Needham reiterated its Buy rating for the stock on February 20, 2020, while the target price for the stock was revised from $50 to $48.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 17 ’23 when Forbes William P bought 25,000 shares for $1.09 per share. The transaction valued at 27,250 led to the insider holds 79,000 shares of the business.
Collard Craig A bought 150,000 shares of HRTX for $137,970 on Nov 16 ’23. The Chief Executive Officer now owns 186,496 shares after completing the transaction at $0.92 per share. On Nov 16 ’23, another insider, Duarte Ira, who serves as the EVP, Chief Financial Officer of the company, bought 85,000 shares for $0.89 each. As a result, the insider paid 75,599 and bolstered with 85,000 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.47.
Stock Price History:
Over the past 52 weeks, HRTX has reached a high of $3.22, while it has fallen to a 52-week low of $0.50.
Shares Statistics:
A total of 150.29M shares are outstanding, with a floating share count of 142.67M. Insiders hold about 5.10% of the company’s shares, while institutions hold 71.17% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by RTX Corporation analysts. The consensus estimate for the next quarter is $394.17, with high estimates of $26.89 and low estimates of $2.93.
